Vivendal Comp 320 mg/12,5 mg Filmdragerad tablett

국가: 스웨덴

언어: 스웨덴어

출처: Läkemedelsverket (Medical Products Agency)

지금 구매하세요

환자 정보 전단 환자 정보 전단 (PIL)
22-04-2018
제품 특성 요약 제품 특성 요약 (SPC)
22-04-2018

유효 성분:

hydroklortiazid; valsartan

제공처:

Sandoz A/S

ATC 코드:

C09DA03

INN (International Name):

hydrochlorothiazide; valsartan

복용량:

320 mg/12,5 mg

약제 형태:

Filmdragerad tablett

구성:

valsartan 320 mg Aktiv substans; hydroklortiazid 12,5 mg Aktiv substans

수업:

Apotek

처방전 유형:

Receptbelagt

치료 영역:

Valsartan och diuretika

제품 요약:

Förpacknings: Blister, 7 tabletter (plast/Al); Blister, 7 tabletter (Al); Blister, 10 tabletter (Al); Blister, 14 tabletter (Al); Blister, 15 tabletter (Al); Blister, 20 tabletter (Al); Blister, 28 tabletter (Al); Blister, 30 tabletter (Al); Blister, 50 tabletter (Al); Blister, 56 tabletter (Al); Blister, 60 tabletter (Al); Blister, 84 tabletter (Al); Blister, 90 tabletter (Al); Blister, 98 tabletter (Al); Blister, 100 tabletter (Al); Blister, 280 tabletter (Al); Blister, 10 tabletter (plast/Al); Blister, 14 tabletter (plast/Al); Blister, 15 tabletter (plast/Al); Blister, 20 tabletter (plast/Al); Blister, 28 tabletter (plast/Al); Blister, 30 tabletter (plast/Al); Blister, 50 tabletter (plast/Al); Blister, 56 tabletter (plast/Al); Blister, 60 tabletter (plast/Al); Blister, 84 tabletter (plast/Al); Blister, 90 tabletter (plast/Al); Blister, 98 tabletter (plast/Al); Blister, 100 tabletter (plast/Al); Blister, 280 tabletter (plast/Al); Blister, 50 x 1 tabletter, endos (Al); Blister, 50 x 1 tabletter, endos (plast/Al)

승인 상태:

Godkänd

승인 날짜:

2011-04-15

환자 정보 전단

                                PACKAGE LEAFLET: INFORMATION FOR THE USER
Vivendal Comp 80 mg /12.5 mg film-coated tablets
Vivendal Comp 160 mg /12.5 mg film-coated tablets
Vivendal Comp 160 mg /25 mg film-coated tablets
Vivendal Comp 320 mg /12.5 mg film-coated tablets
Vivendal Comp 320 mg /25 mg film-coated tablets
Valsartan/hydrochlorothiazide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Vivendal Comp is and what it is used for
2.
What you need to know before you take Vivendal Comp
3.
How to take Vivendal Comp
4.
Possible side effects
5.
How to store Vivendal Comp
6.
Contents of the pack and other information
1.
WHAT VIVENDAL COMP IS AND WHAT IT IS USED FOR
Vivendal Comp film-coated tablets contain two active substances called
valsartan and
hydrochlorothiazide. Both of these substances help to control high
blood pressure (hypertension).

VALSARTAN belongs to a class of medicines known as “angiotensin II
receptor antagonists”,
which help to control high blood pressure. Angiotensin II is a
substance in the body that
causes vessels to tighten, thus causing your blood pressure to
increase. Valsartan works by
blocking the effect of angiotensin II. As a result, blood vessels
relax and blood pressure is
lowered.

HYDROCHLOROTHIAZIDE belongs to a group of medicines called thiazide
diuretics (also
known as “water tablets”). Hydrochlorothiazide increases urine
output, which also lowers
blood pressure.
Vivendal Comp is used to treat high blood pressure which is not
adequately controlled by a single
substance a
                                
                                전체 문서 읽기
                                
                            

제품 특성 요약

                                MARKNADSFÖRS EJ FÖR NÄRVARANDE.
_Produktinformation_
                                
                                전체 문서 읽기
                                
                            

다른 언어로 된 문서

환자 정보 전단 환자 정보 전단 영어 18-03-2022
제품 특성 요약 제품 특성 요약 영어 16-01-2019
공공 평가 보고서 공공 평가 보고서 영어 21-02-2013